NEW YORK (GenomeWeb News) – Toronto-based GeneNews said that it has issued five-year, 15 percent redeemable convertible secured debentures in the aggregate principal amount of C$1.1 million (US$900,000).
 
The issuance represents the initial closing of a private placement offering of debentures, under which the firm’s board of directors has authorized the sale of up to C$3.45 million in debentures. The 15 percent annual interest will be paid upon the earlier of maturity, conversion, or redemption of the debentures.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.